Latest Us Market News

Cettire reports a 3% dip in sales revenue for Q1 FY26 but posts a $10 million quarterly EBITDA improvement, driven by strong growth outside the US. The luxury e-commerce platform is navigating a challenging market with a focus on profitability and geographic diversification.

Vitrafy Life Sciences has delivered its first production unit of the next-generation cryopreservation device, advanced its US commercial footprint, and maintained a strong financial position heading into FY2026.

Genetic Signatures Ltd reports a robust start to FY2026 with a 20% quarterly sales increase, driven by new US contracts and strong growth in EMEA and Australia. The company also bolsters its leadership with a new CTO appointment.

Jindalee Lithium has successfully raised $8 million through a private placement, complemented by a $1 million Share Purchase Plan, to advance its McDermitt Lithium Project and a strategic US SPAC transaction.

Singular Health Group has advanced its US expansion through the deployment of 3DICOM™ licenses under a key contract with Provider Network Solutions, alongside appointing a new US commercial chief to drive growth.

Orthocell has boosted its investment in Marine Biomedical to secure exclusive global distribution rights for PearlBone™, an innovative bone substitute nearing FDA approval, enhancing its regenerative medicine portfolio.

Zip Co Limited has reported a near doubling in cash earnings for Q1 FY26, driven by robust transaction growth and improved operating leverage, particularly in the US market. The company also doubled its share buy-back program and raised its US transaction volume growth guidance.

Power Minerals Limited is set to list on the US OTCQB market following strong investor interest after acquiring the Gamma Heavy Rare Earths and Uranium Project in California, aiming to boost liquidity and visibility in the US capital markets.

Orthocell has raised $30 million through an institutional placement to accelerate the US commercialisation of its flagship nerve repair product Remplir and expand its regenerative medicine portfolio.

PainChek Limited has appointed Sasha Grant as Head of Growth for its AI-powered Infant App, aiming to scale its presence in a $15 billion global market. Early Australian adoption shows promising conversion rates as the company prepares for international expansion.

Adveritas Limited has reported a record annualised recurring revenue of $12.2 million for the September 2025 quarter, driven by strong affiliate momentum and initial commercialisation of its Meta integration. The company is advancing its US expansion with a robust trial pipeline and expects significant contract conversions in the coming quarter.

PainChek Limited has confirmed FDA De Novo classification for its PainChek Adult App, promptly disclosing the material regulatory milestone to the ASX and signalling a significant step towards US market entry.